Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative ...

In this Healio Video Perspective from Hawaiian Eye 2025, Greg Kunst, CEO of Aurion Biotech, discusses positive phase 1/2 data for the company’s cell therapy for corneal endothelial disease.

(C) NS and KD cells were analyzed for MT and Smad2/3 interaction by PLA for Tubulin and Smad2/3 with or without TGFβ treatment. PLA dots represent Smad2/3 and β-tubulin interaction. Graph shows the ...

New branches form through special cells at the leading edges of blood vessels—endothelial tip cells—migrating to new locations, where they form vascular sprouts. Efficient cell migration is ...

SING IMT improved distance and near vision in AMD patients, with minimal impact on corneal endothelial cell density and manageable safety outcomes. At 6 months post-surgery, 97.1% of patients achieved ...